The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries
Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties.
GSK to purchase $9 million in shares of Spero common stock
LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license…
Source link